Suven Pharmaceuticals announces today that the US Food and Drug Administration (USFDA) has issued an EIR for its wholly owned Subsidiary Casper Parma, a finished dosage drug Manufacturer for human use. The pre- approval inspection was conducted during 25 July 22 through 29 July 22. Pre-Approval Inspections covering of three applications: NDA 016084, ANDA 217020, & ANDA 217030. The inspection concluded with no observation (FDA-483) issued. EIR received from US FDA states that the site is recommended for approval of the three NDA & ANDA listed above. Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
